Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Anti-CD80 (Galiximab), Human IgG1, lambda Antibody

Recombinant monoclonal antibody manufactured using Recombinant Platform with variable regions from the therapeutic antibody IDEC-114 (Galiximab) to detect CD80 expression in humans
Catalog #: A2011
$625.00

Product Details

Size 200 μg
Antibody Target CD80
Alternate Name B7-1; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7
Host Recombinant
Antibody Type Monoclonal
Isotype Human IgG1, lambda
Immunogen Galiximab was prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subs
Accession # P33681
Gene ID 941
Appearance Colorless liquid
Concentration 1 mg/ml
Formulation PBS with 0.02% Proclin 300
Purification Protein A affinity purified
Species Reactivity Human
Application Block, Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Flow Cytometry, Western Blotting, Modulate, ELISA
Application & Usage WB, ELISA, IP, IF, IHC, FC, Block, Modulate
Handling The antibody solution should be gently mixed before use.
Storage Conditions -20ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to CD80. CD80 is a surface glycoprotein and a member of the B7 family of co-stimulatory molecules. CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed constitutively on various subtypes of B-cell lymphomas. Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-κB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximab affects CD28 and CD152 interactions with CD80.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.